Umirolimus

Umirolimus

Chemical structure of Umirolimus

Umirolimus is a pharmaceutical drug that acts as an immunosuppressant. It is a derivative of sirolimus, also known as rapamycin, and is used primarily in the context of drug-eluting stents to prevent restenosis in patients undergoing percutaneous coronary intervention.

Mechanism of Action

Umirolimus works by inhibiting the mammalian target of rapamycin (mTOR), a key regulatory kinase involved in cell proliferation, growth, and survival. By blocking mTOR, umirolimus effectively reduces the proliferation of smooth muscle cells in the arterial wall, which is a major factor in the development of restenosis.

Clinical Use

Umirolimus is primarily used in cardiology as a coating for drug-eluting stents. These stents are placed in coronary arteries to keep them open after procedures such as angioplasty. The drug coating helps to prevent the re-narrowing of the artery by inhibiting excessive tissue growth.

Development and Approval

Umirolimus was developed as part of efforts to improve the outcomes of coronary stenting procedures. It has been evaluated in various clinical trials to assess its efficacy and safety compared to other drug-eluting stents. The results have generally shown that umirolimus-coated stents are effective in reducing the incidence of restenosis.

Side Effects

As with other immunosuppressive agents, the use of umirolimus can be associated with certain side effects. These may include an increased risk of infection, delayed wound healing, and potential interactions with other medications. Patients receiving umirolimus-coated stents are monitored for these potential adverse effects.

Related Pages

• Sirolimus
• Drug-eluting stent
• Percutaneous coronary intervention
• Coronary artery disease